CD4 and neoplasm: In 2009 Banissi and coworkers reported that low-dose metronomic TMZ regimens (0.5 and 2 mg/kg for 21 days) induced a significant decrease in Foxp3+Treg/CD4+ ratios in the spleen of tumor-bearing animals [19].